DIFFERENCES BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN TREATING RHEUMATOID ARTHRITIS
Article Sidebar
Main Article Content
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint damage. Treatment options have evolved significantly with the development of targeted therapies such as Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF) inhibitors. This article explores the differences between these two classes of drugs in terms of mechanism of action, efficacy, safety, and clinical application
Article Details
References
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., Del Carmen Morales, L., Reyes Gonzaga, J., ... & Fleischmann, R. (2017). Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine, 376(7), 652–662. https://doi.org/10.1056/NEJMoa1608345
Fleischmann, R., Schiff, M., van der Heijde, D., Elewaut, D., Breedveld, F., Furst, D. E., ... & Keystone, E. (2012). Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine, 367(6), 495–507. https://doi.org/10.1056/NEJMoa1112525
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., ... & Kavanaugh, A. (2018). Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis: a randomized phase 3 trial. Arthritis & Rheumatology, 70(4), 535–546. https://doi.org/10.1002/art.40322
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., ... & McNaughton, C. (2016). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology, 68(1), 1–26. https://doi.org/10.1002/art.39480